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Background: Atherosclerosis is the leading etiologic factor of Atherosclerotic Cerebral Infarction (ACI). Previous
studies have shown that thrombin activatable fibrinolysis inhibitor (TAFI) may play an important role in the
occurrence of acute cerebral infarction, and the levels of TAFI are affected by several single nucleotide polymorphisms
(SNPs) located in the regulatory and coding regions of the gene encoding TAFI. The present study aimed to determine
whether polymorphisms (TAFI –2345 2G/1G, –1690 A/G, –438 A/G, +1583 A/T) of the TAFI gene were associated with
ACI in a Han Chinese population.
Methods: The variant genotypes were identified by restriction fragment length polymorphism (RFLP) and allele-specific
polymerase chain reactions (AS-PCR) in 225 patients with ACI and 184 age-matched healthy individuals.
Results: There was a significant difference in the genotype and allele frequencies of TAFI –2345 2G/1G and −1690
A/G polymorphisms between the ACI and control subjects. Further stratification analysis by gender revealed that
the presence of the –438 AA genotype and the A allele conferred a higher risk of developing ACI in male patients
(p < 0.05). Haplotype analysis demonstrated that four haplotypes of TAFI are significantly associated with ACI.
Conclusions: Our study provides preliminary evidence that the TAFI –2345 2G/1G and –1690 A/G polymorphisms are
associated with ACI susceptibility in a Han Chinese population.
Keywords: Thrombin activatable fibrinolysis inhibitor (TAFI), Atherosclerotic Cerebral Infarction (ACI), PolymorphismBackground
Thrombin activatable fibrinolysis inhibitor (TAFI), also
known as carboxypeptidase B2 (CPB2), is a basic carboxy-
peptidase [1,2]. TAFI can be activated by trypsin-like en-
zymes, such as thrombin, plasmin, and the thrombin/
thrombomodulin complex. Activated TAFI removes
C-terminal lysine residues on plasmin-modified, par-
tially degraded fibrin and attenuates the rate of plas-
minogen activation, thus playing a significant role in* Correspondence: yusenchen163@163.com; likeshen1971@126.com
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unless otherwise stated.blood coagulation and fibrinolysis. An imbalance be-
tween the processes of coagulation and fibrinolysis is one
of the main contributors to thrombosis, a key factor for
the onset of atherosclerotic cerebral infarction (ACI)
[1,3-5]. Impaired fibrinolysis may also be a risk factor for
arterial thrombotic events [6]. In addition, an increased
plasma TAFI concentration may be a risk factor for mul-
tiple diseases, including stable angina pectoris [7], coron-
ary artery disease [8,9], myocardial infarction (MI) [10],
and venous thrombosis [11-13]. Therefore, the risk of
cardiovascular disease, in general, may be decreased by
lowering plasma TAFI levels.
The TAFI gene maps to chromosome 13q14.11, spans
approximately 48 kb and contains 11 exons. Several
SNPs located in the flanking region of TAFI have beenhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Methods and primers used in genotyping of
TAFI −438 A/G, +1583 A/T, −1690 A/G and −2345 2G/1G
polymorphisms
Gene polymorphisms Analysis Primers
TAFI −438 A/G PCR-RFLP Forward:ACCAATGGGAATGTAGG
Reverse:CCTTGCCTCTGACTTTT
TAFI +1583 A/T PCR-RFLP Forward:CTTGGCATGTCATTAGG
Reverse:TGCGGCATTTGTTGACA






Common Reverse b: CACTGAAG
GAGAGAAAG






Common Reverse b: TGTTCCCTT
GCAGTTTAGC
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Franco et al. demonstrated that polymorphisms in the
TAFI promoter determine plasma antigen levels and
may influence the risk of venous thrombophilia [14].
Henry et al. revealed that circulating levels of TAFI are
strongly determined by polymorphic variations in the
promoter and the 3'-untranslated region (UTR) of the
TAFI gene [15]. In addition, Biswas et al. determined
that TAFI antigen levels were significantly associated
with the disease phenotype and with TAFI polymor-
phisms [17]. These findings suggest that TAFI polymor-
phisms may play a role in modulating plasma TAFI
antigen level, and thus contribute to ACI phenotype.
Association studies between polymorphisms of TAFI
and stroke have been reported for many different origin
populations, but with conflicting results [17-19]. Akatsu
et al. found no statistical correlation between TAFI
Ala147Thr and Thr325Ile polymorphisms and cerebral
infarction [18]. Ladenvall et al. also did not find any as-
sociation between genetic variants of TAFI and overall
ischemic stroke, but they did find an increased risk be-
tween TAFI polymorphisms and stroke subtypes [20].
More recently, Kozian et al. found that the Ile/Ile geno-
type at position 325 of TAFI is associated with the inci-
dence of stroke and the age at onset of first stroke [19].
Furthermore, the incidence of stroke is higher in TAFI
Ile325Ile patients with predisposing risk factors for
thrombotic events, such as diabetes mellitus, myocardial
infarction or hypertension [19]. These lines of evidence
suggest a role for TAFI polymorphisms in the pathogen-
esis of stroke. However, the association between TAFI
polymorphisms and ACI has not yet been determined.
Therefore, the present study aims to evaluate the exist-
ence of an association between four polymorphisms
(−2345 2G/1G, –1690 A/G, –438 A/G and +1583 A/T)




The study recruited 225 patients with ACI (145 males
and 80 females) from the Department of Neurology at
the Affiliated Hospital of Guangdong Medical College
in China between 2011 and 2013. Patients’ diagnoses
were verified with either computed tomography (CT)
or magnetic resonance imaging (MRI) and were clinico-
neuropathologically confirmed. Patients were classified
into subtypes according to the Trial of Org 10172 in Acute
Stroke Treatment (TOAST) classification [21]. Patients
with transient ischemic attacks, cardiogenic cerebral in-
farctions, cerebral hemorrhage, coronary artery diseases,
autoimmune diseases, systemic inflammatory diseases,
blood diseases, or malignant tumors were excluded from
this study. Additional information recorded included age,gender, cerebrovascular disease risk factors and previous
and ongoing medication or systemic therapy.
A total of 184 matched controls (107 males and 77
females) were recruited from the Health Examination
Center of the Affiliated Hospital of Guangdong Medical
College during the same time period. These control pa-
tients were comparable to the ACI subjects in age, sex,
and race. The same exclusion criteria were used as above.
Written informed consent was obtained from each par-
ticipant prior to enrollment in the study. The study was
approved by the ethics committee of Guangdong Medical
College and was conducted according to the principles of
the Declaration of Helsinki.
Genotyping of TAFI polymorphisms
Genomic DNA was extracted from peripheral blood
using the EZ-10 Spin Column Whole Blood Genomic
DNA Isolation Kit (Sangon Biotech®, Shanghai, China)
according to the manufacturer’s instructions. Four TAFI
SNPs (−2345 2G/1G, –1690 A/G, –438 A/G and +1583
A/T) were selected according to previous findings [15].
Genotyping of the TAFI gene for the presence of –438
A/G and +1583 A/T mutations was performed by poly-
merase chain reaction (PCR) and restriction fragment
length polymorphism (RFLP); TAFI –2345 2G/1G and –
1690 A/G mutations were identified by allele-specific
polymerase chain reaction (AS-PCR). The primers used
are listed in Table 1. The PCR and RFLP analysis were
Table 3 Allele and genotype frequencies of the TAFI
polymorphisms in ACI patients and controls
TAFI Polymorphisms Frequency










Li et al. Lipids in Health and Disease 2014, 13:80 Page 3 of 7
http://www.lipidworld.com/content/13/1/80performed as described previously [22]. For quality con-
trol, we sequenced 5% DNA samples directly for each
SNP, and no inconsistencies were detected. The results
were read and interpreted in a blind fashion, without
knowledge of the patient’s designated group.
Statistical analysis
All statistical tests were performed using SPSS 19.0 soft-
ware (IBM, Armonk, NY, USA). The Hardy-Weinberg
equilibrium and differences in the gene and allele fre-
quencies between groups were assessed using a χ2 test.
The allele and genotype frequency differences between
patient cases and healthy controls were assessed by Fisher's
exact test or the chi-square test. For comparisons resulting
in significant statistical values, an odds ratio (OR) with a
95% confidence interval (95% CI) was calculated by com-
paring the total number of each allele found among the
cases and controls. Haplotype analyses were conducted by
SHEsis software (http://analysis.bio-x.cn/myAnalysis.php)
[23]. All p values reported were two-tailed. Statistical sig-
nificance was defined as p < 0.05.
Results
Baseline characteristics
The clinical characteristics of the 409 participants (225
ACI patients and 184 control subjects) are presented in
Table 2. Conventional risk factors, including smoking,
hypertension, and diabetes, were significantly more com-
mon in the ACI group than in the control group. There
were no significant differences in age or sex between the
ACI patients and controls. The mean ages of the ACI
and control patients were 67.60 years old (±10.61 years)
and 66.11 years old (±11.02 years), respectively. In ACI
patients, the blood glucose levels tended to be higher
than in the controls, but the high-density lipoproteinTable 2 General characteristics of patients with ACI and
controls
Variables Cases (n = 225) Controls (n = 184)
Age (years) (mean ± SD) 67.60 ± 10.61 66.11 ± 11.02
Sex (male/female) 145/80 107/77
Smoking (%, n) 21.8%(49) * 13.0%(24)
Hypertension 64.4%(145) * 23.9%(44)
Diabetes 23.1%(52)* 6.0%(11)
Blood glucose levels (mmol/L) 6.51 ± 2.60* 5.43 ± 1.70
Cholesterol (mmol/L) 5.17 ± 1.35 5.30 ± 1.18
Triglyeride (mmol/L) 1.23 ± 0.72 1.27 ± 0.86
High density lipoprotein (HDL)
(mmol/L)
1.28 ± 0.28* 1.45 ± 0.41
Low density lipoprotein (LDL)
(mmol/L)
3.36 ± 1.02 3.31 ± 0.94
*P < 0.05.(HDL) levels were lower at admission. The cholesterol,
triglyceride and low-density lipoprotein (LDL) levels of
the ACI patients were not significantly different from
those of the healthy control patients.
Genotype and allele frequencies of TAFI polymorphisms
in ACI patients and controls
The genotype and allele frequencies of the TAFI gene
polymorphisms are shown in Table 3. No deviation from
the Hardy-Weinberg equilibrium for the polymorphisms
examined was observed in the genotype distributions of
the ACI patients and controls (data not shown).
The comparison of genotype distributions between the
ACI subjects and control subjects revealed that there
was a statistically significant association between the –
2345 2G/1G and –1690 A/G polymorphisms of TAFI
and the risk of ACI. The 2G versus 1G allele frequencies
of the TAFI –2345 2G/1G polymorphism were 57.1%
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of the TAFI –2345 2G/2G (p = 0.017, OR = 0.550, 95%
CI: 0.335-0.903) genotype and the −2345 2G (p = 0.024,
OR = 0.727, 95% CI: 0.551-0.959) allele frequencies was
significantly higher in patients than in controls. Likewise,
the A versus G allele frequencies of the TAFI –1690 A/G
polymorphism were 70.2% versus 29.8% among the pa-
tient cohort and 62.5% versus 37.5% among control sub-
jects (p < 0.05). The prevalence of the –1690 AA genotype
(p = 0.048; OR = 1.488, 95% CI: 1.002-2.209) and the –
1690 A allele (p = 0.048; OR = 1.488, 95% CI: 1.002-2.209)
frequencies was significantly higher in patients than in
controls. No differences in the –438 A/G and +1583 A/T
genotype and allele frequencies were observed between
ACI cases and control subjects (Table 3).
Stratification of the genotype and allele frequencies of TAFI
polymorphisms in ACI patients and controls by gender
When stratified by gender, a significant difference was
found in the frequency of the A allele of the TAFI –438
A/G polymorphism between male ACI patients and male
controls (p = 0.039; OR = 1.549 (95% CI: 1.020-2.353).
In female individuals, no significant difference of geno-
type or allelic distribution was found between the ACI
and control groups. We did not observe differences of
TAFI +1583 A/T, –2345 2G/1G and –1690 A/G geno-
type and allele frequencies between ACI patients and
controls when separated by gender (Table 4).
Haplotype analysis
We found a total of 16 haplotypes. Four haplotypes in
which the frequency of the haplotype was greater than
5% in ACI cases and controls were included in the
haplotype analysis. The haplotypes included yielded
strongly significant associations (Table 5). The frequency
of haplotypes H2 (2G/A/G/A) and H3 (2G/A/G/T) was
significantly higher in the ACI case group than in the
control group (p = 0.026; p = 0.002, respectively); whereas
the haplotype frequencies for H1 (1G/G/G/T) and H4
(2G/G/G/T) were lower in the ACI cases (p = 0.015 and
p = 0.001, respectively).
Discussion
The results of the present study provide evidence that
the variant –2345 2G/1G and –1690 A/G polymorphismsTable 4 Subgroup analysis of TAFI -438A/G polymorphism ge
Gender Group Number GG
Male Cases 145 75(51.7%)
Controls 107 65(60.7%)
Female Cases 80 47(58.8%)
Controls 77 43(55.8%)
*Compare with control group, P < 0.05.of TAFI are associated with the risk of developing ACI in
contrast with the –438 A/G and +1583 A/T polymor-
phisms. To the best of our knowledge, this result is the first
to suggest an association of the –2345 2G/1G and –1690
A/G polymorphisms of TAFI with ACI in a Chinese popu-
lation. Further stratification by gender revealed that the –
438 A/G polymorphism of TAFI is associated with ACI in
male patients. In addition, haplotype analysis demonstrated
that four haplotypes are significantly associated with ACI.
TAFI is a 58-kDa plasma glycoprotein secreted by he-
patocytes as an inactive form [24]. Upon activation by
thrombin, plasmin, or the thrombin-thrombomodulin
complex, TAFI is transformed into a carboxypeptidase
B-like enzyme (TAFIa) [2,25]. TAFIa plays an important
role in regulating the balance between coagulation and
fibrinolysis by inhibiting fibrinolysis. Previous studies
have indicated that high levels of TAFI in circulating
plasma increase the risk of cardiovascular death during
the acute phase of ischemic stroke [24]. In addition, re-
cent studies have reported that TAFI deficient mice are
also susceptible to intracerebral thrombosis and ische-
mic stroke [26]. These lines of evidence lead to the hy-
pothesis that TAFI is of pathogenic significance to ACI.
Several studies have analyzed the relationship between
TAFI polymorphisms and cardiovascular disease, with
different and even contradictory conclusions drawn from
various ethnical populations. While one study found that
the 147Thr allele of the Ala147Thr polymorphism pro-
tected against MI [27], in another study, the 147Thr al-
lele was associated with a higher risk of angina [28].
TAFI polymorphisms C+1542G and Thr325Ile were also
found to be related to the type of ACS [29] and throm-
botic microangiopathies [30]. Regarding cerebrovascular
diseases, Akatsu et al. did not find any association be-
tween the Ala147Thr and Thr325Ile polymorphisms of
TAFI and cerebral infarction [18]. However, a pro-
spective cohort study in Europe demonstrated that the
Thr325Ile polymorphism of TAFI is associated with the
incidence of stroke and the age at onset of first stroke in
patients [19]. Ladenvall et al. did not find any association
between a series of tagging SNPs of the TAFI gene, but
an increased risk was found between TAFI polymor-
phisms and stroke subtypes [20]. In the present study, we
show, for the first time, that the −2345 2G/1G and −1690
A/G polymorphisms of TAFI were associated with ACI innotype and allele frequencies of the men and women
GA AA G A
57(39.3%) 13(9.0%)* 207(71.4%) 83(28.6%)*
40(37.4%) 2(1.9%) 170(79.4%) 44(20.6%)
30(37.4%) 3(3.8%) 124(77.5%) 36(22.5%)
27(35.1%) 7(9.1%) 113(73.4%) 41(26.6%)
Table 5 Association analysis of TAFI haplotypes
NO Haplotypes Cases Controls P OR 95% CI
−2345 −1690 −438 +1583
H1 1G G G T 22.71(5.0%) 34.50(9.4%) 0.015 0.512 0.296 ~ 0.887
H2 2G A G A 25.50(5.7%) 9.26(2.5%) 0.026 2.328 1.083 ~ 5.005
H3 2G A G T 131.72(29.3%) 72.87(19.8%) 0.002 1.684 1.212 ~ 2.340
H4 2G G G T 19.64(4.4%) 37.62(10.2%) 0.001 0.399 0.227 ~ 0.703
Only haplotypes whose frequency was >5% in both cases and controls were included in the Table.
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the four polymorphisms investigated in the present study
were in strong linkage disequilibrium with each other
and with the previously described Ala147Thr poly-
morphism [15]. It is most likely that these polymor-
phisms function synergistically to contribute to the disease
phenotype.
It has been widely recognized that plasma TAFI levels
are strongly genetically controlled [17,31]. TAFI levels are
under the control of several SNPs located in the regulatory
and coding regions of the TAFI gene [17,18,25,32]. A
transethnic study using fine mapping of quantitative trait
nucleotides (QTNs) underlying TAFI antigen levels identi-
fied that the −2345 2G/1G SNP located in the 5' region
might be one of the QTNs [33] and that −2345 1G alleles
were independently associated with increased TAFI levels.
The −1690 A/G polymorphism is located two bases down-
stream from a potential binding site for the HFH3 tran-
scription factor, and the −438 A/G polymorphism is
located one base downstream from a potential binding
site for the VBP transcription factor [14]. These polymor-
phisms may alter the binding of the corresponding tran-
scription factors to the promoter, thus affecting promoter
activity and contributing to varied TAFI expression. In
the 3’-UTR, there are three transcription termination
sites [34]. The interaction of cis-acting elements within
the 3'-UTR of TAFI with IL-1 and IL-6 significantly in-
creased the stability and frequency of mRNA transcripts
[35]. In addition, polymorphisms in the 3’-UTR may alter
TAFI mRNA abundance by influencing mRNA process-
ing or stability. The haplotype carrying the +1583 T allele
reduces the stability of TAFI transcripts, suggesting
the +1583 A/T allele is also related to TAFI antigen
levels [14,15]. Data from Africans and Europeans con-
verged to identify the 1583 T/A polymorphism as one of
the QTNs contributing to elevated TAFI levels. In sum,
polymorphisms both in the promoter and 3’-UTR regions
of TAFI can affect the binding of transcription factors or
mRNA stability, thereby influencing gene expression.
The stratified analysis by gender revealed that among
males, those with the variant −438 A allele and AA
genotype had a significantly higher risk of ACI, while
among women, no statistical significance was found.TAFI levels in patients with polycystic ovary syndrome
(PCOS) were significantly higher than in control groups
[36,37]. It is known that PCOS patients express high
levels of androgen [36,37]. The androgen may affect
TAFI production by some unknown mechanism. There-
fore, it is conceivable that the −438 AA allele that is as-
sociated with higher androgen levels could also increase
TAFI levels in male ACI patients. However, more func-
tional studies on the relationship between sex hormones
and TAFI levels should be carried out.
In genes with multiple susceptibility alleles, particu-
larly when the LD between polymorphisms is weak,
haplotype-based association studies have advantages
over analyses based on individual polymorphisms [38]. In
the present study, haplotype analysis identified four hap-
lotypes significantly associated with ACI. H1(1G/G/G/T)
and H4(2G/G/G/T) were associated as protective haplo-
types, while H2(2G/A/G/A) and H3(2G/A/G/T) were
risk haplotypes. The haplotype carrying the G allele
of −1690 is a protective haplotype, while the A allele
of −1690 is a risk haplotype. Ladenvall et al. found that
TAFI genotypes and haplotypes showed significant asso-
ciations with TAFI levels. While no haplotype was found
to have a significant association with overall ischemic
stroke, subtype analysis revealed an association between
the H2B haplotype and cryptogenic stroke and an associ-
ation between the H1B haplotype and small-vessel dis-
ease [20]. As these results illustrate, haplotype analysis
is helpful for deciphering the relationship between
multiple SNPs and disease susceptibility. Our findings
suggest that the haplotype of TAFI could be genetic a
marker for ACI.
There are several limitations to this study. The small
number of participants in this study was insufficient and
therefore may have led to non-representative results.
This limitation may have suppressed a true relationship
due to a type II statistical error. A sample size with suffi-
cient statistical power is critical to analyze the genetic
associations of causal genes with complex diseases sus-
ceptibility. The sample size for detecting associations be-
tween disease and SNP markers is known to be highly
affected by disease prevalence, disease allele frequency,
linkage disequilibrium, inheritance models (e.g., additive,
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the genetic variants (e.g., odds ratio, relative risk, etc.).
Particular attention must be paid to sample sizes when
more than one variable is studied simultaneously, such
as multiple imperfectly correlated traits, intergenic inter-
actions or gene-environment interactions [39]. Addition-
ally, the comparatively small sample size, together with
other environmental risks may mask the genuine differ-
ences in allele frequencies between cases and controls.
Hong et al. suggested that a lower sample size for testing
more common SNPs with stronger effect sizes and in-
creased LD between marker allele and disease allele
might contribute to achieve adequate statistical power
[40]. Therefore, our results should be interpreted with
caution. In addition, selection bias in the patient or con-
trol populations cannot be entirely excluded. The other
clinical characteristics of the study group, such as hyper-
tension, diabetes or hypercholesterolemia, might have
complicated the associations between TAFI polymor-
phisms and ACI. Other functional polymorphisms might
also influence TAFI expression, and their combined ef-
fects must be studied to improve the prediction of the
occurrence, severity, and outcomes of ACI. Furthermore,
the levels of TAFI were not evaluated. However, the pri-
mary purpose of our study was to establish a genetic refer-
ence for future studies. Thus, this investigation focused on
assessing the association of different genetic polymor-
phisms of TAFI with the risk of developing ACI. Larger
patient and control cohorts will be needed to confirm the
association of TAFI gene polymorphisms with ACI in
other populations.
Conclusion
Our study is the first to describe the existence of an as-
sociation between the −2345 2G/1G and −1690 A/G
polymorphisms of TAFI and the risk of developing ACI
in a Chinese population. Our findings support the idea
that polymorphisms of TAFI contribute to the develop-
ment of ACI. Our study may provide clues for the evalu-
ation of individual susceptibility to ACI as well as for
effective measures for the control and prevention of
ACI. More work is required to shed light on the role of
TAFI in the pathogenesis of ACI and to further clarify
its prognostic and therapeutic potential.
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